[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"renal-cyst\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:renal-cyst":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,74,95],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100371079","a-prospective-observational-study-of-foam-sclerotherapy--100371079",false,"NCT04111692","A Prospective Observational Study of Foam Sclerotherapy .","A Prospective Observational Study of Foam Sclerotherapy for the Treatment of Symptomatic Kidney or Liver Cysts in Patients With Autosomal Dominant Polycystic Kidney and Liver Disease.","Inclusion Criteria:\n\n* Age ≥18 years\n* Clinical diagnosis of ADPKD or ADPLD\n* 1-3 large, non-exophytic liver or kidney cyst\n* Compressive symptoms from dominant cyst\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Absence of ADPKD or ADPLD\n* Largest cyst \\\u003C4cm in all 3 dimensions or largest cyst volume \\\u003C400cc\n* \\>3 large, non-exophytic liver or kidney cyst(s) ≥4cm in all 3 dimensions (cyst volume ≥400cc)\n* Unwilling to comply with study follow-up protocol to 12 ± 1months post-FS\n* Lacking capacity to provide informed consent to FS of liver or kidney cysts\n* Pregnancy","ALL","18 Years","100 Years",{"count":20,"type":21},100,"ESTIMATED","OBSERVATIONAL","An observational prospective study to determine the impact of foam sclerotherapy of large, dominant kidney\u002Fliver cysts on quality of life outcomes and kidney\u002Fliver cyst volumes at up to 12 months of follow-up in patients with autosomal dominant polycystic kidney disease (ADPKD) and autosomal dominant polycystic liver disease (ADPLD).",[25,26,27,28],"Autosomal Dominant Polycystic Kidney","Renal Cyst","Autosomal Dominant Polycystic Liver Disease","Hepatic Cyst",[30,31,32,33],"hepatic cyst","Kidney Cyst","Autosomal Polycystic Liver Disease","Autosomal Polycystic Kidney Disease","RECRUITING","2026-01-22",{"date":37,"type":38},"2026-01-26","ACTUAL",{"date":40,"type":38},"2017-11-06",{"date":42,"type":21},"2027-11",{"name":44,"class":45},"Mayo Clinic","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":55,"targetDuration":57,"studyType":22,"phases":4,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":46},"100616352","ai-for-renal-tumors-using-non-contrast-ct-100616352","NCT07304492","AI for Renal Tumors Using Non-Contrast CT","An Artificial Intelligence Model for Screening and Diagnosis of Renal Tumors Based on Non-Contrast CT","Inclusion Criteria:\n\n1. Patients who underwent an abdominal CT examination.\n2. Patients with renal lesions were managed according to standard clinical pathways, which included follow-up, biopsy, or surgery.\n3. Malignant lesions were pathologically confirmed; benign lesions were confirmed by either pathological diagnosis or imaging follow-up.\n4. No prior treatment had been received for the renal disease.\n\nExclusion Criteria:\n\n1. Patients refuse to undergo recommended follow-up, biopsy, or surgery, which precluded definitive diagnosis of the renal lesion.\n2. Absence of complete pathological confirmation for lesions suspected to be malignant.\n3. Patients have received any form of prior treatment for the renal lesion.\n4. Poor image quality that hampered diagnostic evaluation.","80 Years",{"count":56,"type":21},10000,"6 Months","The goal of this observational study is to learn whether the artificial intelligence method can automatically identify and diagnose renal lesions using non-contrast CT or opportunistic screening.",[60,26],"Renal Neoplasms",[62,60,26,63],"Artificial intelligence","Computer tomography","NOT_YET_RECRUITING","2025-12-13",{"date":67,"type":38},"2025-12-26",{"date":69,"type":21},"2026-01",{"date":71,"type":21},"2028-12",{"name":73,"class":45},"Fudan University",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":81,"targetDuration":57,"studyType":22,"phases":4,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":4},"100607379","ct-kub-in-renal-cysts-100607379","NCT07187791","CT KUB in Renal Cysts","Validation of CT KUB in Assesment of Renal Cysts","Inclusion Criteria:\n\n* Patients referred for CT KUB with detectable Renal cysts\n\nExclusion Criteria:\n\n* 1-Patients with known renal tumors.\n* 2-Inadequate imaging quality: CT KUB with severe motion\u002Fstreak artifact or incomplete anatomical coverage preventing lesion assessment.",{"count":82,"type":21},200,"1. Primary (main):\n\n   1\\. Determine the diagnostic accuracy of CT KUB in differentiating between benign and suspicious renal cysts according to the Bosniak classification.\n2. Secondary (subsidiary):\n\n   1. Assess interobserver agreement in CT KUB interpretation among radiologists with varying levels of expertise.\n   2. Identify limitations and pitfalls in the use of non-contrast CT KUB for characterizing renal cysts.",[85,26],"CT KUB","2025-09-16",{"date":88,"type":38},"2025-09-23",{"date":90,"type":21},"2025-10-01",{"date":92,"type":21},"2027-10-31",{"name":94,"class":45},"Assiut University",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":104,"phases":105,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":46},"100576780","enhanced-recovery-after-urologic-surgery-100576780","NCT06789744","Enhanced Recovery After Urologic Surgery","Enhanced Recovery After Urologic Surgery: a Prospective Observational Study Comparing Regional with Conventional Anesthetic Techniques","Inclusion Criteria:\n\n* any age.\n* American Society of Anesthesiologists (ASA) physical status classification of I-III.\n* undergo urological surgery.\n* receive one of the following analgesic techniques: epidural analgesia (EA), paravertebral block (PVB), transversus abdominis plane (TAP) block, intravenous patient-controlled analgesia (PCA), or intrathecal morphine.\n* provided voluntary informed consent.\n\nExclusion Criteria:\n\n* a bleeding disorder or coagulopathy.\n* infection at the intended puncture site or systemic infection.\n* a known allergy to local anesthetics.\n* spinal deformity or spinal injury.\n* a psychiatric disorder that could impair their ability to cooperate with the study protocol.\n* pregnant or breastfeeding.\n* severe cardiovascular or pulmonary dysfunction.\n* chronic opioid use (defined as \\>1 month) at high doses.",{"count":103,"type":21},150,"INTERVENTIONAL",[106],"NA","This clinical trial aims to investigate the analgesic efficacy of several perioperative pain management strategies-specifically, epidural analgesia, paravertebral blockade, transversus abdominis plane (TAP) block, intravenous patient-controlled analgesia (PCA), and intrathecal morphine-in patients undergoing a range of urological procedures. These procedures include pediatric circumcision, hydrocelectomy, inguinal hernia repair, renal cyst excision, and transurethral resection of the prostate. The trial will also evaluate the safety profiles of two specific local anesthetics, liposomal bupivacaine and ropivacaine. The primary research question is whether these different analgesic techniques reduce postoperative opioid requirements in patients undergoing urological surgery. A secondary question explores the adverse events associated with the use of liposomal bupivacaine and ropivacaine in this population.\n\nParticipants will be:\n\nUrological surgery patients undergoing one of the aforementioned procedures. These participants will be randomized to receive one of the following pain management modalities: epidural analgesia, paravertebral blockade, TAP block, intravenous PCA, or intrathecal morphine. Patient assessments will be conducted in the post-anesthesia care unit (PACU) and at 2, 6, 12, and 24 hours postoperatively. Outcome measures will include: Numeric Rating Scale (NRS) pain scores, total postoperative analgesic consumption, recovery status, patient satisfaction, and time to return of bowel function.",[109,110,111,26,112],"Circumcision","Hydrocelectomy","Hernia","Prostate","2025-01-22",{"date":115,"type":38},"2025-01-24",{"date":117,"type":21},"2025-02-01",{"date":119,"type":21},"2025-05-20",{"name":121,"class":45},"Xiaguang Duan"]